PARP1 inhibition is used when there is no or reduced activity of BRCA1 in the tumor, antibody treatments are used when the tumor overexpresses the Epidermal Growth Factor Receptor (EGFR), c-KIT tyrosine kinase inhibitors are used when it overexpresses c-KIT, and multikinase inhibitors are used when EGFR is overexpressed [7,11,13]. The gene discussed is PARP1; the disease is neoplasm.